Sutro Biopharma Inc. Common Stock
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Overview
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$4.7700 |
Previous Close Volume |
229940 |
Latest News
- Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones 13 May 2024 16:52:35
- Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial 30 Apr 2024 08:23:27
- Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering 02 Apr 2024 06:23:05
- Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors 02 Apr 2024 01:23:23
- Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones 25 Mar 2024 16:53:12
- Sutro Biopharma to Participate in Upcoming Investor Conferences 06 Feb 2024 16:08:34